Olympus has signed a definitive agreement to acquire BioProtect, an Israel-based medical device manufacturer developing implant technologies for prostate cancer care. The $270 million acquisition is expected to be completed by the end of the second quarter of calendar year 2026, subject to customary closing conditions. The transaction marks an expansion of Olympus’s contributions to oncology and urology, aligning with its corporate strategy to accelerate cutting-edge technologies focused on patient safety and outcomes.<\/p>\n\n\n\n
BioProtect’s flagship Balloon Spacer system is designed to provide consistent spacing between the prostate and other critical structures, protecting healthy tissues during prostate cancer radiation therapies. After treatment, the implant naturally biodegrades. Since its commercial introduction in 2023, the Balloon Spacer has been used in more than 11,000 procedures worldwide, with studies indicating the device’s contribution to preserving gastrointestinal, urinary, and sexual functions for patients. Prostate cancer is the second most diagnosed form of cancer among men worldwide, with an estimated 1.5 million patients diagnosed annually.<\/p>\n\n\n\n
Seiji Kuramoto, Executive Officer and Surgical and Interventional Solutions Division Head at Olympus, stated that by combining BioProtect’s strengths with Olympus’s global reach and relationships with healthcare professionals, Olympus can expand access to solutions that support better patient outcomes. Itay Barnea, Chief Executive Officer of BioProtect, added that the deal represents a significant advancement for BioProtect, its physician partners, and ultimately the patients served. BioProtect, headquartered in Israel and established in 2004, has 130 employees and manufacturing locations in Israel, with revenue of approximately $14.5 million in 2025.<\/p>\n","protected":false},"excerpt":{"rendered":"
Olympus has signed a definitive agreement to acquire BioProtect for $270 million, adding the company’s biodegradable Balloon Spacer system for prostate cancer radiation therapy to expand its urological technologies portfolio.<\/p>\n","protected":false},"author":2,"featured_media":39680,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[488,681,27,10,671],"tags":[768,595,33],"class_list":["post-39679","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","category-care-therapy","category-middle-east-africa","category-strategic-development","category-top-news","tag-israel","tag-ma","tag-olympus"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/39679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/comments?post=39679"}],"version-history":[{"count":3,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/39679\/revisions"}],"predecessor-version":[{"id":39684,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/posts\/39679\/revisions\/39684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media\/39680"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/media?parent=39679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/categories?post=39679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/wp-json\/wp\/v2\/tags?post=39679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}